Background: Anti-epidermal growth factor receptor (EGFR) rechallenge is a standard therapeutic option for patients with RAS/BRAF wild-type (WT) metastatic colorectal cancer (mCRC) who benefited from prior anti-EGFR-based regimens. Circulating tumor DNA (ctDNA)-guided molecular selection improved efficacy, but routine testing and real-world evidence remain limited. Methods: REalCHALLENGE is a retrospective study aiming at assessing the activity of real-world anti-EGFR rechallenge versus other standard-of-care (SoC) treatments in microsatellite stable (MSS), RAS/BRAF WT mCRC patients profiled by ctDNA. The primary endpoint was overall response rate (ORR), while secondary endpoints included disease control rate (DCR), progression-free survival (PFS), and overall survival (OS). Hyperselection integrating archival solid tissue profiling to ctDNA profiling was also investigated. Results: 104 patients were included: 69 (66%) ctDNA RAS/BRAF WT and 35 (34%) mutants. Among ctDNA WT, anti-EGFR rechallenge led to higher ORR compared with SoC (29% vs 0%, p = 0.003), and DCR (68% vs 42%, p = 0.049). A trend toward longer median PFS was observed (4.7 vs 2.9 months, p = 0.06), alongside with improved OS (21.9 vs 11.1 months, p = 0.04). In ctDNA mutant patients, outcomes were comparable between groups. In hyperselected non-mutant patients, anti-EGFR rechallenge led to improved ORR (34.4% vs 0%; p = 0.006), PFS (4.98 vs 2.59 months; p = 0.02) and OS (22.20 vs 11.18 months; p = 0.02). No new safety signals emerged. Conclusions: Anti-EGFR rechallenge confirmed meaningful activity in ctDNA RAS/BRAF WT MSS mCRC patients in a real-world setting, particularly in a hyperselected population integrating ctDNA and solid tissue profiling. These findings support the value of molecular profiling to optimize selection for anti-EGFR rechallenge.

Real-world anti-EGFR rechallenge in circulating tumor DNA-profiled metastatic colorectal cancer: the REalCHALLENGE study

Puccini, Alberto;Simonelli, Matteo;
2026-01-01

Abstract

Background: Anti-epidermal growth factor receptor (EGFR) rechallenge is a standard therapeutic option for patients with RAS/BRAF wild-type (WT) metastatic colorectal cancer (mCRC) who benefited from prior anti-EGFR-based regimens. Circulating tumor DNA (ctDNA)-guided molecular selection improved efficacy, but routine testing and real-world evidence remain limited. Methods: REalCHALLENGE is a retrospective study aiming at assessing the activity of real-world anti-EGFR rechallenge versus other standard-of-care (SoC) treatments in microsatellite stable (MSS), RAS/BRAF WT mCRC patients profiled by ctDNA. The primary endpoint was overall response rate (ORR), while secondary endpoints included disease control rate (DCR), progression-free survival (PFS), and overall survival (OS). Hyperselection integrating archival solid tissue profiling to ctDNA profiling was also investigated. Results: 104 patients were included: 69 (66%) ctDNA RAS/BRAF WT and 35 (34%) mutants. Among ctDNA WT, anti-EGFR rechallenge led to higher ORR compared with SoC (29% vs 0%, p = 0.003), and DCR (68% vs 42%, p = 0.049). A trend toward longer median PFS was observed (4.7 vs 2.9 months, p = 0.06), alongside with improved OS (21.9 vs 11.1 months, p = 0.04). In ctDNA mutant patients, outcomes were comparable between groups. In hyperselected non-mutant patients, anti-EGFR rechallenge led to improved ORR (34.4% vs 0%; p = 0.006), PFS (4.98 vs 2.59 months; p = 0.02) and OS (22.20 vs 11.18 months; p = 0.02). No new safety signals emerged. Conclusions: Anti-EGFR rechallenge confirmed meaningful activity in ctDNA RAS/BRAF WT MSS mCRC patients in a real-world setting, particularly in a hyperselected population integrating ctDNA and solid tissue profiling. These findings support the value of molecular profiling to optimize selection for anti-EGFR rechallenge.
2026
Anti-EGFR
Cetuximab
Colon and rectal cancer
Liquid biopsy
Panitumumab
Reintroduction
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11699/110603
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact